Nitrogen use efficiency (NUE) products appear poorly matched to potato physiology and provide little benefit to the crop, ...
Pale and yellow corn doesn’t necessarily indicate a nitrogen deficiency. The Late Spring Nitrate Test is one way to find out.
High nitrogen losses by ammonia volatilization are expected when urea is used as the source of N. The use of controlled-release urea and urease inhibitors are possible strategies to reduce such losses ...
The Urease Inhibitor Market is positioned at a pivotal juncture, driven by escalating demand across agriculture, healthcare, and environmental sectors. This report delivers an in-depth evaluation of ...
The Germany Urease Inhibitors Market currently holds a significant position within the broader agricultural and pharmaceutical sectors, with an estimated market value of approximately USD 150 million ...
What Is Sotyktu, and Why Does It Matter? Sotyktu (deucravacitinib) is an oral selective tyrosine kinase 2 (TYK2) inhibitor used to treat autoimmune inflammatory diseases such as plaque psoriasis in ...
Deucravacitinib (Sotyktu) — an oral, selective tyrosine kinase 2 (TYK2) inhibitor — has received FDA approval for the treatment of adults with active psoriatic arthritis (PsA), the drug’s manufacturer ...
Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...
ABSTRACT: In Campeche Mexico, corn production is particularly very important due to its large area of medium and high-yield potential. For any plan production, soil fertility needs to be understood ...
Patients may self-administer Voyxact after receiving proper training on subcutaneous injection technique. The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® ...
The FDA has approved a Novartis drug for chronic spontaneous urticaria (CSU), providing patients an oral treatment alternative to currently available injectable medications. The regulatory decision ...
Novartis has pegged multibillion-dollar peak sales for remibrutinib based on its potential to expand into multiple immunology indications. (Novartis) Novartis has scored the FDA’s approval for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results